期刊文献+

对抗凝患者的规范化药学监护模式探讨 被引量:11

Exploration of standardized pharmacy practice model for anticoagulation therapy
原文传递
导出
摘要 目的探索临床药师参与抗凝治疗管理的切入点与规范化药学监护模式。方法结合国外抗凝治疗目标及权威指南,以一例抗凝患者的药学监护工作为例,系统分析临床药师在抗凝治疗及综合治疗过程中发现监护点、改善治疗效果的途径和方法。结果通过对抗凝患者的全程化药学监护,逐步建立药师参与临床抗凝治疗管理的规范化工作模式。结论药师在抗凝治疗团队中深入开展规范化药学监护,可更好地保障患者用药安全。 Objective To explore pharmaceutical care points and standardized pharmacy practice model for anticoagulation therapy. Methods Through the use of National Patient Safety Goals and guidelines, pharmacy practices were conducted and care points were searched for a patient receiving anticoagulants by clinical pharmacists to improve the outcome of patient therapy. Results Pharmaceutical care was provided for the patient by clinical pharmacist, and a standardized practice model for anticoagulation therapy management that involve clinical pharmacists was established. Conclusion Standardized practices for anticoagulation therapy performed by clinical pharmacists can improve rational drug use and highlight the value of clinical pharmacists.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2014年第3期227-228,231,共3页 The Chinese Journal of Clinical Pharmacology
关键词 临床药师 抗凝治疗管理 药学监护 clinical pharmacist anticoagulation therapy management pharmacy practice
  • 相关文献

参考文献6

  • 1The Joint Commission. National patient safety goals effective January 1, 2013. Hospital accreditation program [EB/OL]. http:// www. jointcommission, org/assets/'l/18/NPSG _ Chapter _ Jan2013 _ HAP. pdf, 2013 -03 - 14.
  • 2Kearon C, Akl EA, Comerota AJ, et al. Antithrembotic therapy for VTE disease, antithrombotic therapy and prevention of thrombosis (9th ed) :American College of Chest Physicians evidence - based clinical practice guidelines [ J]. Chest, 2012,141 ( Suppl. ) : Se44 - Se88 ,Se419 - Se494.
  • 3杨婷,徐斌,杨洁,王红娟,张玉霄,尹彤.定期随访对出院患者应用华法林抗凝治疗效果与安全性的影响[J].药物不良反应杂志,2010,12(5):309-312. 被引量:5
  • 4Wittkowsky AK, Nutescu EA, Blackburn J, et al. Outcomes of oral anticoagulant therapy managed by telephone vs in - office visits in an anticoagulation clinic setting[ J]. Chest, 2006,130 : 1385 - 1389.
  • 5Institute for Safe Medication Practices. Example of a health care fail- ure mode and effects analysis for anticoagulants [ EB/OL]. http:// www. ismp. org/Tools/FMEAofAnticoagulants, pdf, 2013 -03 -14. Institute for Safe Medication Practices. ISMP's list of high - alert medications [ EB/OL]. http ://www. ismp. org/Tools/institutionalhi- ghMert, asp, 2013 -03 - 14.
  • 6Institute for Safe Medication Practices. ISMP's list of high - alert medications [ EB/OL]. http ://www. ismp. org/Tools/institutionalhi- ghMert, asp, 2013 -03 - 14.

二级参考文献10

  • 1Caldwell MD,Awad T,Johnson JA,et al.CYP4F2 genetic variant alters required warfarin dose[J].Blood,2008,111(8):4106-4112.
  • 2Zhang JE,Jorgensen AL,Alfirevic A,et al.Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy[J].Pharmacogenet Genomics,2009,19(10):781-789.
  • 3Yael Lurie,Ronen Loebstein,Daniel Kumik,et al.Warfarin and vitamin K intake in the era of pharmacogenetics[J].Br J Clin Pharmacol,2010,70(2):164-170.
  • 4Booth SL,Al Rajabi A.Determinants of vitamin K status in humans[J].Vitam Horm,2008,78:1-22.
  • 5Thane CW,Paul AA,Bates C J,et al.Intake and sources of phyUoquinone (vitamin K1):variation with socio-demographic and lifestyle factors in a national sample of British elderly people[J].BrJ Nutr,2002,87(7):605-613.
  • 6Usui Y,Tanimura H,Nishimura N,et al.Vitamin K concentrations in the plasma and liver of surgical patients[J].Am J Clin Nutr,1990,51(2):846-852.
  • 7Holbrook AM,Pereira JA,Labiris R,et al.Systematic overview of warfarin and its drug and food interactions[J].Arch Intern Med,2005,165(3):1095-1106.
  • 8何华,马长生.华法林抗凝强度的监测及意义[J].中华老年多器官疾病杂志,2008,7(6):526-528. 被引量:7
  • 9郑华,史旭波,胡大一.华法林钠的规范应用[J].临床荟萃,2009,24(14):1197-1199. 被引量:10
  • 10岳林峰.抗凝药物华法林的安全应用[J].药学与临床研究,2009,17(5):397-399. 被引量:33

共引文献4

同被引文献73

  • 1胡大一,周自强,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状流行病学研究[J].中国心脏起搏与心电生理杂志,2004(z1):3-6. 被引量:32
  • 2张庆莉,李双成,隋丙运,陈炳东.临床药学服务干预对社区慢性病患者社会支持生活质量及治疗依从性的影响[J].中国行为医学科学,2007,16(5):413-415. 被引量:18
  • 3鲁端.心房颤动合并房室传导阻滞的若干认识[J].心电学杂志,2007,26(3):186-189. 被引量:21
  • 4余自成.药学监护工作中的药物咨询和患者用药教育[J].中国临床药学杂志,2007,16(5):318-320. 被引量:29
  • 5卫生部.抗菌药物临床应用指导原则.卫办医政发[2009]38号.
  • 6European Heart Rhythm Association, European Association for Cardio - Thoracic Surgery, Carom A J, et al. Guidelines for the nmnagement of at- rial fibrillation : the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) [ J ]. Eur Heart J, 2010, 31:2369 - 2429.
  • 7中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南(2009)[J].中华心血管病杂志,2009,37:4-25.
  • 8Bfiguori C, Airoldi F, Moriei N, et al. New pharmacological protocols to prevent or reduce contrast media nephropathy [ J ]. Minerva Cardioangiol, 2005,53:49 -58.
  • 9赵志刚,黄佳.我国抗凝管理有待规范[N].中国医药报,2013-05-15.
  • 10European Heart Rhythm Association, European Association for Cantiothoracic Surgery, Camm A J, et al. Guidelines for the management of atrial fibrillation:the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europacc, 2010, 12 (10) : 1360-420.

引证文献11

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部